avatar for Kerensa Saljooqi

Kerensa Saljooqi

Emalex Biosciences Inc.
Sr. Director, Clinical Operations
Data science and AI are being incorporated early in drug development to help detect subject phenotypes and allow us to enrich the patient population with subjects who are likely to respond to treatment. Digital tech is being trialed to detect trends compared to standard primary endpoint instruments. Study candidates have increasing awareness of clinical trials and are actively informed. The regulators are challenging drug developers to bring novel modalities early in experiments and seek their guidance. What does this mean for clinical research? It’s not business as usual, that’s for sure! With over 25 years of clinical ops/dev experience, Kerensa manages studies using beta devices, manual audio file sharing, designed data portals, conducted UAT of newly designed mobile apps and more!

My Speakers Sessions

Wednesday, January 22